ARCT

Arcturus Therapeutics Holdings Stock Analysis

AI Rating

Low
  • Quality1/10
  • Growth↓ 3/10
  • Momentum↓ 2/10
Arcturus Therapeutics Holdings sales and earnings growth
ARCT Growth
Neutral
  • Revenue Y/Y↓ -39.15%
  • EPS Y/Y↓ -5.13%
  • FCF Y/Y↓ 4.82%
Arcturus Therapeutics Holdings gross and profit margin trends
ARCT Profitability
Low
  • Gross margin ↑ 100.00%
  • EPS margin↓ -68.30%
  • ROIC↓ -220.10%
Arcturus Therapeutics Holdings net debt vs free cash flow
ARCT Risk
Great
  • Debt / Equity↓ 0.1
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -5.4

Arcturus Therapeutics Holdings stock volatility is higher than the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗